Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/780366

Contents of this Issue

Navigation

Page 7 of 47

6 Clinical OMICs January/February 2017 www.clinicalomics.com News Guardant to Launch 500-Plus-Gene Liquid Biopsy Panel for Big Pharma In Januay, Guardant Health entered into separate agreements with Astra- Zeneca, Merck, and Pfizer to develop a 500-plus-gene liquid biopsy panel to meet the needs of pharmaceutical companies for broad, molecular testing on a platform that doesn't require tis- sue samples. At launch, expected mid-year, Guar- dant says the 500-plus-gene panel will be industry's largest commercially available liquid biopsy panel. It will allow researchers to screen patients for multiple clinical trial options from a simple blood draw, while also allow- ing real-time monitoring of tumor response and the evolution of tumor resistance. It will also support analysis of tumor mutational burden, for use with immunotherapy trials. "With Guardant360, we have pushed our digital sequencing platform to the biological limits of DNA sequencing sensitivity. In a number of cases, we are now confidently detecting a single molecule of mutant, circulating tumor DNA in a 10-mL tube of blood drawn from an advanced cancer patient," said Helmy Eltoukhy, Guardant Health CEO and co-founder. "Now we are applying this same underlying technology to 10 times as many genomic targets, in an effort to speed drug development. The result for which we are aiming is that effective drugs will get to market faster and help patients sooner." Intellia Joins 100,000 Genomes Project Intellia Therapeutics repor ted in mid-January that it joined the Genom- ics England Genomics Expert Network for Enterprises (GENE) Consortium, as the first dedicated genome-editing company to participate in the 100,000 Genomes Project. "Access to genomics information is critical as Intellia looks to better understand the basis of disease and to develop potential genome-edit- ing treatments," said Intellia's CEO and founder, Nessan Bermingham, Ph.D. "We look forward to actively partic- ipating in the GENE Consortium, as Genomics England is enabling scientific exploration and key medical insights that ultimately will benefit patients." Intellia is one of 12 other companies working together in a precompetitive trial. The collaboration aims to iden- tify the most effective and secure way of bringing industry expertise into the 100,000 Genomes Project, to realize future potential benefits for patients affected by rare diseases or cancers. As a member of the Consortium, Intellia is granted controlled access to aggre- gated, deidentified genome and health data of participants—all managed by experts specializing in data analysis with the goal optimizing data gener- ated by the project. Sir John Chisholm, executive chair- man, Genomics England, said: " The potential for genomics to transform healthcare, from better diagnoses to new drugs and treatments, is extraor- dinary. We are delighted to welcome Intellia Therapeutics to our GENE Con- sortium. The U.K. is a global leader in population sequencing and it's import- ant for the future of medicine that we continue to attract and collaborate with the most innovative emerging technologies in this space." 10x Genomics, PerkinElmer to Jointly Offer Automated NGS Solutions 10x Genomics and PerkinElmer plan to jointly offer automated next-gener- ation sequencing (NGS) solutions, by combining 10x's sequencing platform with PerkinElmer's automation solu- tions. The result, the companies says, will aid researchers with a streamlined and enhanced NGS workflow. "Our collaboration with Perkin- Elmer underscores 10x's commitment to advancing the way we look at and understand genetic information," says Serge Saxonov, co-founder and CEO of 10x Genomics. "As genomic research becomes more and more prominent, access to 10x solutions will illuminate a more comprehensive understanding of disease." Under the agreement, PerkinElmer will develop automation protocols for use with the 10x Genomics Chro- mium System, 10x's core technology. Alex Raths / Getty Images a_crotty / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017